Harm reduction and control of HIV in IDUs in France

The Lancet

Volumn 372, Issue 9637, 2008, Pages 448-

  Carrieri, M Patrizia ^a,b   Spire, Bruno ^a,b,c  

^a AIX MARSEILLE UNIV   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c AIDES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; OPIATE;

DRUG SUBSTITUTION; DRUG WITHDRAWAL; FRANCE; HARM REDUCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PUBLIC HEALTH; SUBSTITUTION THERAPY;

EID: 48649106642     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61195-2     Document Type: Letter

References (5)

1. Csete J., and Wolfe D. Progress or backsliding on HIV and illicit drugs in 2008?. Lancet 371 (2008) 1820-1821
2. Carrieri M.P., Amass L., Lucas G.M., Vlahov D., Wodak A., and Woody G.E. Buprenorphine use: the international experience. Clin Infect Dis 43 suppl 4 (2006) S197-S215
3. Emmanuelli J., and Desenclos J.C. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003. Addiction 100 (2005) 1690-1700
4. Jauffret-Roustide M., Emmanuelli J., Quaglia M., et al. Impact of a harm-reduction policy on HIV and hepatitis C virus transmission among drug users: recent French data-the ANRS-Coquelicot Study. Subst Use Misuse 41 (2006) 1603-1621
5. Anon. Stratégies thérapeutiques pour les personnes dépendantes des opiacés: place des traitements de substitution. Conférence de consensus-Fédération française d'addictologie; Lyon, France; June 23-24, 2004.